Table 8, Strength of evidence for drugs versus CBT - Anxiety in Children

Warning: The NCBI web site requires JavaScript to function. more...

Table 8Strength of evidence for drugs versus CBT

Comparison	Outcome	Conclusion	Study Design and Sample Size^a	Factors That Affect the Strength of Evidence^b	Overall Evidence Strength (Direction of Effect)
Fluoxetine (class: SSRI) vs. CBT	Primary anxiety, child report	SMD:−0.16; 95% CI: −0.55 to 0.24; I²=N/A	1 RCT (102 Patients)⁵¹	Severe imprecision (wide CIs and small sample size)	Low (no difference)
	Primary anxiety, clinician report	SMD:0.78; 95% CI: 0.37 to 1.18; I²=N/A	1 RCT (102 Patients)⁵¹	Imprecision (small sample size)	Moderate (increased anxiety)
	Function	SMD: 0.54; 95% CI: 0.14 to 0.94; I²=N/A	1 RCT (102 Patients)⁵¹	Imprecision (small sample size)	Moderate (reduced function)
	Secondary measure	SMD: 0.51; 95% CI: 0.11 to 0.90; I²=N/A	1 RCT (102 Patients)⁵¹	Imprecision (small sample size)	Moderate (increased anxiety)
	Social function	SMD: −0.19; 95% CI: −0.58 to 0.21; I2=N/A	1 RCT (102 Patients)⁵¹	Severe imprecision (wide CIs and small sample size)	Low (no difference)
Sertraline (class: SSRI) vs. CBT	Primary anxiety, clinician report	SMD: −0.15; 95% CI: −0.31 to 0.02; I²= N/A	1 RCT (272 Patients)^{7, 67, 69–73}	Severe imprecision (wide CIs and small sample size)	Low (no difference)
	Function	SMD: −0.12; 95% CI: −0.35 to 0.12; I²= N/A	1 RCT (272 Patients)^{7, 67, 69–73}	Severe imprecision (wide CIs and small sample size)	Low (no difference)
	Remission	RR: 0.57; 95% CI: 0.48 to 0.69; I²=N/A	1 RCT (272 Patients)^{7, 67, 69–73}	Imprecision (small sample size)	Moderate (reduced remission)
	Response	RR: 0.97; 95% CI: 0.80 to 1.17; I²=N/A	1 RCT (272 Patients)^{7, 67, 69–73}	Severe imprecision (wide CIs and small sample size)	Low (no difference)

: CI: confidence interval, CBT: cognitive behavioral therapy, N/A: not applicable, RCT: randomized control trial, RR: relative risk, SMD: standardized mean difference, SNRI: serotonin–norepinephrine reuptake inhibitor, SSRI: selective serotonin reuptake inhibitor, TCA: Tricyclic antidepressants
a: The sample size includes the number of patients from each comparison.
b: Only SOE domains that led to rating down SOE are reported in this column. Domains that are not reported were satisfactory.

From: Results

Anxiety in Children [Internet].

Comparative Effectiveness Reviews, No. 192.

Wang Z, Whiteside S, Sim L, et al.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Aug.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.